MKI67 and neoplasm: Comparison between therapy-guided expression at both the mRNA and protein levels showed high consensus between the common biomarkers to differentiate tumor from stroma regions (higher level of EpCAM, pan-cytokeratin, and ki67), indicating general robustness of this technology for proteogenomic co-profiling.